All In Biotech

Drug Trial Radar · NCT07483554

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of IBI343 in Combination Therapy for Patients With Advanced Malignant Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

389

Planned (sponsor's estimate)

Start

Apr 20, 2026

Primary completion

Mar 31, 2028

Study completion Mar 31, 2028

Sponsor

Sponsor type
Industry
First posted
Mar 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination therapy for patients with advanced malignant solid tumors.Enrollment of subjects with advanced gastric/gastroesophageal junction adenocarcinoma positive for CLDN18.2, and subjects with pancreatic ductal adenocarcinoma positive for CLDN18.2.

Conditions

  • CLDN18.2 Positive
  • Gastric/Gastroesophageal Junction Adenocarcinoma
  • Pancreatic Ductal Adenocarcinoma

Interventions

  • IBI343,Gemcitabine, Albumin-bound PaclitaxelDrug

    IBI343,Gemcitabine, Albumin-bound Paclitaxel intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) evaluated according to RECIST v1.1Time frame: Up to 24 months
  2. Incidence of Adverse Events (AE)Time frame: Up to 24 months
  3. Incidence of treatment-emergent adverse Events (TEAE)Time frame: Up to 24 months
  4. Incidence of adverse events of Special Interest (AESI)Time frame: Up to 24 months
  5. Incidence of serious adverse events (SAE)Time frame: Up to 24 months
  6. Number of participants with abnormal laboratory tests resultsTime frame: Up to 24 months
  7. Number of subjects with clinically significant changes in physical examination resultsTime frame: Up to 24 months
  8. Number of subjects with clinically significant changes in vital signsTime frame: Up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.